Table of contents

From basic to applied research, prototypes and products

contribution by Birthe Sandargo, Marc Stadler

Strategies against human disease

  1. 1.

    Antibacterial antibiotics

    contribution by Clara Chepkirui, Benjarong Thongbai, Marc Stadler,

  2. 2.

    Antimycotics

    contribution by Benjarong Thongbai, Marc Stadler

  3. 3.

    Biofilm inhibitors

    contribution by Benjarong Thongbai, Marc Stadler

  4. 4.

    Anti-cancer agents

    contribution by Chayanard Phukhamsakda, Marc Stadler

  5. 5.

    Anti-diabetes

    contribution by Achala R. Rathnayaka, Marc Stadler

  6. 6.

    Improving nerve functioning

    contribution by Benjarong Thongbai, Marc Stadler

  7. 7.

    Fungi in Traditional Chinese Medicine

    contribution by Thatsanee Luangharn, Marc Stadler

  8. 8.

    Cardiovascular disease control by fungi

    contribution by Anuruddha Karunarathna, Marc Stadler

  9. 9.

    Antiviral agents

    contribution by Allan Patrick G. Macabeo, Marc Stadler

  10. 10.

    Immunosuppressive and immunomodulatory agents from fungi

    contribution by Clara Chepkirui, Marc Stadler

Strategies against plant disease

  1. 11.

    Biocontrol of plant disease using endophytes

    contribution by Nimali I. de Silva, Siraprapa Brooks

  2. 12.

    Biocontrol of insects using fungi

    contribution by Allen Grace T. Niego

  3. 13.

    Biocontrol of nematodes and fungal nematizides

    contribution by Diana S. Marasinghe, Clara Chepkirui

  4. 14.

    Biocontrol of weeds and herbicides from fungi

    contribution by Pranami D. Abeywickrama, Jiye Yan

  5. 15.

    Fungal antagonists used in post-harvest disease control

    contribution by Binu C. Samarakoon

  6. 16.

    Bio control of rusts and smuts by antagonistic fungi

    contribution by Rashika S. Brahmanage

Enhancing crops and forestry

  1. 17.

    Biofertilizers

    contribution by Mingkwan Doilom

  2. 18.

    Arbuscular mycorrhizae as biofertilizers

    contribution by Amornrat Chaiyasen, Saisamorn Lumyong

  3. 19.

    Application of ectomycorrhizal fungi in forestry contribution by Jaturong Kumla, Saisamorn Lumyong

  4. 20.

    Use of orchid mycorrhizae and endophytes in biotechnology

    contribution by Nimali I. de Silva, Sureeporn Nontachaiyapoom

  5. 21.

    Growth promoting hormones from fungi

    contribution by Saisamorn Lumyong

  6. 22.

    Mitigating abiotic stress in plants: the endophyte method

    contribution by Karaba N. Nataraja, Uma Shaanker Ramanan

Food and beverages from fungi

  1. 23.

    Growing mushrooms in compost

    contribution by Naritsada Thongklang

  2. 24.

    Growing mushrooms in bags

    contribution by Samantha Karunarathna

  3. 25.

    Growing mushrooms in the field

    contribution by Peter E. Mortimer, Samantha C. Karunarathna

  4. 26.

    Modern mushroom production: an automated factory process

    contribution by Jianchu Xu

  5. 27.

    New edible mushrooms

    contribution by Samantha Karunarathna

  6. 28.

    Agaricus subrufescens

    contribution by Naritsada Thongklang

  7. 29.

    Using fungi to enhance food value

    contribution by Danushka S. Tennakoon

  8. 30.

    Food colouring from filamentous fungi

    contribution by Wasan Sriprom and Saisamorn Lumyong

  9. 31.

    Food flavouring

    contribution by S. Nuwanthika Wijesinghe

  10. 32.

    What is mushroom stock? Products, process and flavours contribution by Deping Wei

  11. 33.

    Fungi in making tea

    contribution by Ningguo Liu, Jack JK Lui

  12. 34.

    Wine, beer and spirits

    contribution by Sinang Hongsanan

  13. 35.

    Functional foods and nutraceuticals

    contribution by Boontiya Chuankid

  14. 36.

    Harvesting the untapped probiotic potential of fungi

    contribution by Eleni Gentekaki, Achala R. Rathnayaka

Saving the planet

  1. 37.

    Agricultural waste disposal

    contribution by Putarak Chomnunti, Craig Faulds

  2. 38.

    Mycoremediation: Fungi to the rescue

    contribution by Dulanjalee Harishchandra, Jiye Yan

  3. 39.

    Mycofumigation using Muscodor

    contribution by Nakarin Suwannarach, Saisamorn Lumyong

  4. 40.

    Biomass to biofuel: unmasking the potential of lesser-known fungi

    contribution by Venkat Gopalan, T.S. Suryanarayanan

  5. 41.

    Packed-bed bioreactor for mycomaterial production

    contribution by Peter Mueller, Dan Meeks, Meghan O’Brien, Jake Winiski

  6. 42.

    Fungal degradation of plastics: A hidden treasure for green environment

    contribution by Sehroon Khan, Sadia Nadir

  7. 43.

    Polycyclic aromatic hydrocarbon degradation by basidiomycetes

    contribution by Allen Grace T. Niego, Resurreccion B. Sadaba

  8. 44.

    Can fungi help modify the sustainable soil enhancer biochar?

    contribution by Thitipone Suwunwong, Craig Faulds

Commodities

  1. 45.

    Fungi and cosmetics

    contribution by Erandi Yasanthika

  2. 46.

    Agarwood

    contribution by S. Nuwanthika Wijesinghe

  3. 47.

    Fungal enzymes

    contribution by Pattana Kakumyan

  4. 48.

    Preservatives

    contribution by Benjarong Thongbai

  5. 49.

    Organic acids

    contribution by Janith V.S. Aluthmuhandiram

  6. 50.

    Textile dyes

    contribution by Ruvishika S. Jayawardena

The future

Functional genomics and the search for novel anti-infectives

contribution by K.W. Thilini Chethana, Jiye Yan and Birthe Sandargo

From basic to applied research, prototypes and products

Fungi have both good and bad facets (Pointing and Hyde 2001). They are essential for nutrient cycling because of their ability to degrade cellulose and lignin (Pointing et al. 2001). On the other hand, they cause serious human, animal and plant diseases and have numerous negative aspects on human life (Hyde et al. 2018a). Fungi are, however, also relatively understudied, but are an essential, fascinating and biotechnologically useful group of organisms with an incredible biotechnological potential for industrial exploitation. In this paper, we detail 50 ways in which we can potentially exploit fungi. We provide notes and examples for all potential exploitations and give examples from our own work and the work of others. We also provide a flow chart that can be used to convince funding bodies just how important fungi are and their potential for biotechnological research and potential products.

While several of our chapters are dealing with marketed products that even include blockbuster pharmaceuticals, such as the beta-lactam antibiotics, the statins and cyclosporine, others are dedicated to newly upcoming areas that still remain to be explored. Other chapters treat relatively small market segments that may expand in the future. For example, the consumers around the world now increasingly prefer natural compounds over synthetic chemicals and even in the industrial sectors that produce commodity chemicals, there is now an increased interest in development of sustainable biotechnological processes, in order to obtain new natural products that can eventually replace traditional synthetics. As compared to other biological sources, in particular plants, fungi have the great advantage that they can be grown in large bioreactors at an industrial scale, and suitable processes for their cost-efficient fermentation have been available for many decades, e.g. for production of certain organic acids, enzymes and antibiotics. As exemplified by the recent studies of the Thai mycobiota, modern polyphasic taxonomic approaches are constantly revealing a plethora of new and undescribed species even in the fairly well-known genera of fungi like Agaricus (Hyde et al. 2018b). Even the majority of the known species in the fungal kingdom are virtually untapped with regard to potential applications, also because they were never cultured and studied for their growth characteristics and physiology. New methods and protocols have to be developed for this purpose, and this implies that substantial basic research must be carried out before the exploitation of the novel organisms can be envisaged.

Although fungi have so many potential uses, research on their potential applications is in general poorly funded and much of the research that is being carried out in academia is fundamental, even in areas that belong to the fields of biotechnology and applied mycology. For example, screening fungi for production of antibiotics by antagonistic culture testing has often been reported, but is unlikely to lead to industrial projects. Often, it will take over a decade even to bring a given project based on a novel fungal metabolite into the preclinics, and even this is only possible by joint, interdisciplinary efforts of biologists, biotechnologists, pharmacists and chemists. Moreover, the Big Pharma industry has recently downsized their capacities for in-house research, meaning that the academic sector (sometimes supported by smaller companies or organisations like the Bill and Melinda Gates Foundation and the Wellcome Trust) has become more and more involved in the preclinical evaluation of new compounds.

Investing in basic research may seem, at first sight, a costly affair. However, there are numerous examples of the past demonstrating why investing in basic research pays off in the long run, and even more reasons, why it is today more important than ever to renew an interest in basic research on fungi. But how to convince funders, in particular from the private sector, to invest into researchers doing basic research on fungi?

There are, no doubt, areas of research, which are of utmost importance to the entire world, yet are considered valueless to the pharmaceutical industry. One of these is the search for novel anti-infectives, as the world is running out of antibiotics (Hesterkamp 2017; WHO report 2017). It has long been seen as a tedious process to obtain novel antibiotics from living organisms.

However, the focus in the past has been on the same bacterial and fungal genera, such as Streptomyces in the Actinobacteria and common soil moulds like Aspergillus and Penicillium in the filamentous fungi (Karwehl and Stadler 2017). Since almost no novel carbon skeletons have been discovered from these common soil microbes in the past 20 years, it makes much more sense to study the numerous species that are constantly being discovered and shown to belong to new phylogenetic groups.

In our review, we present fungi, in particular Basidiomycota, as a still underexplored, highly promising source of anti-infectives, immunosuppressants, and other pharmaceuticals (see Badalyan et al. 2019; Sandargo et al. 2019a) that is nowhere near dried up. We give examples on recent developments of turning fungal natural products into commercial drugs and give an overview of the current state of applied research in this field.

In the past, fungal natural products have also led to some blockbusters and various developmental candidate compounds for the agrochemical industry (Bills and Gloer 2016). However, the uncontrolled usage of such fungal pesticides has led to the development of more and more resistances against these agrochemicals (Lucas et al. 2015). A more controlled approach of crop protection is therefore advisable. More basic research is needed to understand natural processes, and thereby allow for the search of natural control agents. In the entries dealing with “Strategies against plant disease”, we show the great potential of fungi as biocontrol agents. We give examples of how fungal biocontrol agents can help save the Agro sector tremendous amounts of money, if companies are given the opportunity to produce cost efficient biocontrol agents. In a likewise manner, the part on Enhancing crops and forestry” deals with the current research on ectomycorrhiza and their potential application as natural biofertilizers.

With the new trend to a more sustainable, health-oriented living, and constant reports of hazardous chemicals found in food and cosmetics, the demand for more ecological, more “natural” alternatives is high. This is again, where fungi can step in. In the entries on “Food and beverages from fungi” and “Commodities”, we present examples of how basic research on fungi has made its way into the food and beverage, but also the textile and flavour industry. Finally, in the part on “Saving the planet” we illustrate the great potential of fungi towards a more sustainable living and how fungi can assist to cope with some potential future challenges that are threatening human civilisation. A diagram illustrating all potential beneficial uses of fungi that are treated herein is given in Fig 1.

Fig. 1
figure 1

Diagram showing the potential use of fungi in biotechnology. The cycle starts with basic biodiversity research, which in turn leads to cultures placed in the central culture collection. The cultures are then used for applied research, which in turn leads to products in the form of the items discussed in the entries of this paper

Strategies against human disease

The scientific community recently celebrated the 90th anniversary of Sir Alexander Fleming’s discovery of penicillin, which marked the starting point of the era of antibiotic chemotherapy. As outlined by Karwehl and Stadler (2017), among the numerous antibiotics that were discovered over the next 50 years, relatively few compound classes were derived from fungi. The latter include the cephalosporins (Newton and Abraham 1955), which belong to the same class as the penicillins, i.e. the beta glucan antibiotics, as well as fusidic acid (Godtfredsen et al. 1962) and pleuromutilin (Novak and Shlaes 2010; Sandargo et al. 2019a). Their chemical structures (14)Footnote 1 are depicted in Fig. 2. Most other commercial antibiotics are actually derived from Streptomyces species and other actinobacteria, or even from other prokaryotes. For details of the history of research on antibiotics, we refer to the review by Mohr et al. (2017), as this does not fall within the scope of the current paper. As we cannot cover the entire field in this paper, we will give a brief overview on antibacterials, antimycotics and biofilm inhibitors and illustrate their usages with some examples of marketed drugs as well as other compounds that have recently been discovered.

Fig. 2
figure 2

Chemical structures of fungal metabolites that were developed to antibacterial drugs

1. Antibacterial antibiotics

The term “antibiotics” is used in the literature with different definitions. The industry mainly use it for antibacterial agents, but the definition that we prefer here, which was adapted from the original one coined by Waksman (1947), i.e., an antibiotic is “a chemical substance, produced by micro-organisms (including fungi), which has the capacity to inhibit the growth of and even to destroy bacteria and other micro-organisms”. The natural functions of antibiotics can easily be explained, resulting from the high competition between fungi, bacteria and other organisms in substrates such as soil, dung and plant debris. If a given organism has acquired the ability to produce a certain secondary metabolite by which it can kill the competing organisms that dwell in the same habitat, it is considered to possess a selective advantage that ultimately increases its fitness (Shearer 1995). Therefore it should come as no surprise that one large experimental study concluded that the majority of filamentous fungi are able to produce antibiotic compounds (Bills et al. 2009). Bills and Gloer (2016) summarized numerous important facts concerning the current state of the art in research on fungal secondary metabolites and concentrated heavily on the biochemical and genetic background of their biosynthesis.

We are currently living in the “post-antibiotic” era, where both, the numbers and percentages of multi-resistant bacterial and fungal pathogens against the established antibiotics are drastically increasing, while the number of new therapeutic agents and developmental candidates has decreased (Cooper and Shlaes 2011). The reasons for this development are manifold, but the phenomenon is primarily due to the fact that the majority of pharmaceutical companies have lost interest in Research and Development on natural products and/or given up their activities in the anti-infectives sector. Experts around the world are now giving warnings about the serious consequences that the lack of antibiotics—in particular against the multi-resistant Gram negative human pathogenic bacteria—can have (Friedman et al. 2016). After two decades of neglect, efforts of both the private and the academic sector on the discovery of new antibiotics have substantially increased.

The pipeline for antibacterial antibiotics (Hesterkamp 2017) shows that there are still some compounds under development, but the majority of those have been optimised from old compounds with known modes of action, e.g. by chemical modifications. Therefore, it is likely that the resistant pathogens will easily find a way to cope with the new products, once they have reached the market. The aforementioned mutilins, which are derived from fermentation of the basidiomycete Clitopilus passeckerianus and subsequent semisynthesis, therefore represent the “newest” compound class that has been registered as an antibacterial drug. A derivative, retapamulin (5), was launched for use as a topical antibiotic against skin infections, and several further derivatives are undergoing clinical trials as systemic antibiotics. In general, basidiomycete cultures are much more difficult to handle with respect to large scale production of secondary metabolites, since they grow rather slowly and often have low yields. For the production of pleuromutilin, however, Bailey et al. (2016) managed to increase the yields substantially after the transfer of the biosynthetic genes into a fast growing heterologous Aspergillus host, which can more easily be handled in the production process. This accomplishment can give rise to some hope that in the future, more of the hitherto neglected, unique biologically active metabolites of basidiomycetes can be made accessible to preclinical development.

2. Antimycotics and fungicides

Whereas multi-resistant bacterial pathogens are very high on the agenda of both the press and funding agencies, relatively little attention is presently being paid to the fact that the number of resistant pathogenic fungi is also on the rise. This topic was treated by Hyde et al. (2018a), we refer to it for the most important ant threatening human pathogenic fungal organisms. In fact, there are only a handful of efficient compound classes on the market that are used in antimycotic chemotherapy, including griseofulvin (6), which was already discovered by Grove et al. (1952; Fig. 3). The newest class of antimycotics that were launched to the market are the echinocandins (e.g., pneumocandin B0 (7) (Denning 2002). The biosynthesis of these highly complex lipopeptides relies on PKS-NRPS hybrid gene clusters (Chen et al. 2013). They are being produced biotechnologically by large scale fermentation using different fungi that are not phylogenetically related and subsequent semisynthesis. The knowledge about the molecular mechanisms of their biosynthesis may in the future lead to the concise manipulation of the production process that can be directed towards new natural derivatives. Interestingly, a comparative genomics study by Yue et al. (2015) has revealed rather high homologies among the biosynthesis gene clusters of the producer organisms that belong to three different classes of Ascomycota, namely Dothideomycetes, Eurotiomycetes, and Leotiomycetes. Possibly, this has been due to horizontal gene transfer during the evolutionary history of these organisms.

Fig. 3
figure 3

Chemical structures of fungal metabolites with antifungal activity against human pathogens

Recent efforts aimed at the discovery of novel antifungal agents have resulted in a number of developmental projects, such as enfumafungin (8) from Hormonema spp. (Peláez et al. 2000). This compound class may soon yield the first pharmaceutical drug for use in humans that originated from a fungal endophyte, over 15 years after their first discovery. Even the biosynthesis genes encoding for these unique triterpenoids (Fig. 3) has only recently been identified (Kuhnert et al. 2018).

The search for novel antimycotics and fungicides has also resulted in the rediscovery of “old” compounds that may become more interesting in the future because they have originally been found in a screening for agrochemical fungicides and were never evaluated for their effects on human fungal pathogens or their mode of action. While the strobilurins, which are a very commercially successful antifungal agents in agriculture (Sauter et al. 1999), have been found inefficient or too toxic for application in humans, many other metabolites with pronounced antifungal effects were apparently never tested on their efficacy against human pathogens. A recent example for such rediscoveries is favolon (9), which is actually a co-metabolite of strobilurins produced by the invasive basidiomycete Favolaschia calocera (Chepkirui et al. 2016) and was originally isolated by Anke et al. (1995). Like the sporothriolodes (10) from the xylarialean fungus Hypoxylon monticulosum (Surup et al. 2014; Fig. 3; now classified in the new genus Hypomontagnella as H. monticulosa; cf. Lambert et al. 2019), this metabolite shows very strong antifungal effects that are not accompanied by prominent cytotoxicity.

3. Biofilm inhibitors

Scientists are exploring different avenues to combat infectious diseases caused by both bacterial and fungal pathogens, for which the inhibition of biofilm formation is one of the most promising leads. Abraham and Estrela (2016) reported that fungal metabolites are becoming increasingly explored for their potential to inhibit the formation of biofilms, e.g. by interfering with quorum sensing, and some compounds have already been discovered that can even destroy pre-formed biofilms. A recent example is coprinuslactone (11) (de Carvalho et al. 2016; Fig 3), a small molecule derived from the edible mushroom Coprinus comatus, which acts against Pseudomonas aeruginosa biofilms. Other examples include roussoellenic acid (12) from a Roussoella sp. (Phukhamsakda et al. 2018), which is active against biofilm formation in Staphylococcus aureus, as well as microporenic acid A (13) from a Kenyan basidiomycete (Chepkirui et al. 2018; Fig. 4), which can not only inhibit biofilm formation in both Staphlococcus aureus and the human pathogenic yeast, Candida albicans, but even destroys pre-formed biofilm in C. albicans at rather low concentrations. These compounds do not have prominent antimicrobial activities and therefore their application is unlikely to raise resistance. The biofilm inhibitors are very promising candidates for use in combination therapy with antibiotics. In several studies, biofilm inhibitors were shown to enhance the activity of the antibiotics by increasing their ability to penetrate the biofilms.

Fig. 4
figure 4

Chemical structures of fungal metabolites with biofilm inhibition activities


These examples illustrate that fungi are under-explored with respect to novel antibiotics and other therapeutic agents, and that it is certainly worthwhile to expend more effort in this area of research with an emphasis on hitherto neglected species from regions and habitats that have not yet been studied systematically. Fungi have much to offer in terms of novel chemistry: due to the advent of revolutionary techniques in genomics, transcriptomics, bioinformatics, analytical chemistry and biotechnological process development, we can now explore the chemical diversity of the mycobiota much more concisely than ever before. Evidence is also accumulating that novel phylogenetic lineages or hitherto neglected taxonomic and ecological groups of fungi can now much more easily be recognized and subjected to the exploitation of their secondary metabolome. However, more public funding is needed to assure that the substantial know-how that has been acquired over many decades does not become forgotten, and that the next generation of researchers will also still be able to work on novel, hitherto unexplored fungal groups, rather than only on model organisms.

4. Anti-cancer agents

Cancer is the second leading cause of mortality after cardiovascular disease, with an estimated 9.6 million cancer-related deaths in 2018 (GBD 2015). Cancer is a multifactorial disease characterized by the loss of growth factors that control the proliferation and division of cells. These abnormal malignant cells can evade the tumour suppressor factors of the human immune system, then develop to tumours and destroy adjacent tissues (Saeidnia and Abdollahi 2014). There are several treatments for cancer, administered according to developmental state of the disease. Chemotherapy, radiation therapy, surgery and immunotherapy are all important elements of cancer treatment. However, while many cytotoxic agents are known to Science (which could in principle serve as chemotherapeutic agents), only few of them specifically target tumour cells and are less toxic to regular, healthy human tissue (Petrelli et al. 2012; Cai et al. 2013; Zugazagoitia et al. 2016). Targeted therapy, usually the conjugated element for cancer treatments, delivers drugs to genes or proteins that are specific to cancer cells or the environmental tissues that promotes the growth of cancer (Padma 2015). Fungi are an importance source for natural product discovery, albeit most anticancer drugs are retrieved from plants and bacteria. In this entry, we describe several promising natural products derived from fungi and highlight some of the chief compounds that are currently in the clinical and preclinical developmental stage (Fig. 5).

Fig. 5
figure 5

Chemical structures of promising natural products derived from fungi with anticancer activity

Irofulven (14) is a semi-synthetic derivative of illudin S (15), a natural toxin isolated from Omphalotus illudens (Jack O’Lantern mushroom; cf. Chin et al. 2006; Movassaghi et al. 2006). Irofulven interferes with DNA replication-complexes and cell division in DNA synthesis. The abnormal cells in S-phase lead to apoptotic cell death (Walser and Heinstein 1973; Jaspers et al. 2002). The anti-tumour activities of irofulven have been evaluated in phase I and II clinical trials with promising results against a variety of cancers, including those in the brain and central nervous system, breast, blood, colon, sarcoma, prostate, lungs, ovarian and pancreas (Alexandre et al. 2004; Miyamoto et al. 2018; Topka et al. 2018). Sandargo et al. (2019a) have recently described the state of the art, including some exciting new illudin conjugates that show superior in vitro activities than irufulven and are presently under early preclinical development.

Aphidicolin (16) is a tetracyclic diterpene with antiviral and antimitotic properties. The compound was originally isolated from “Cephalosporium aphidicola” (currently valid name: Akanthomyces muscarius) and later also reported from Nigrospora sphaerica (Bucknall et al. 1973; Starratta and Loschiavo 1974). Aphidicolin competes for the specific binding site on DNA polymerase α, δ, and ε enzymes. Its mechanism of action and efficacy have been intensively tested in clinical trials (Crosetto et al. 2013; Ayob et al. 2017), but so far it has not become a marketed drug.

Other anticancer lead compounds derived from fungi include leptosins F (17) and C (18) isolated from Leptoshaeria sp., which showed antitumor activity in mouse embryos (Yanagihara et al. 2005; Pejin et al. 2013); β-glucans, the polysaccharides that are naturally found on the cell walls of fungi (Chan et al. 2009; Bashir and Choi 2017); as well as palmarumycin (Powis et al. 2006) and spiropreussione A (Chen et al. 2009). The latter compounds, however, have only demonstrated these activities in vitro, and it is not clear whether they will eventually reach the late exploratory stage of preclinical development.

5. Anti-diabetes

Diabetes mellitus, also known simply as diabetes, is a chronic metabolic disorder (De Silva et al. 2012). People who suffer from diabetes cannot produce or effectively use insulin in the body. Due to this insulin imbalance, they have high amounts of glucose in their blood. There are two common types of diabetes, i.e. type 1 diabetes (insulin dependent diabetes mellitus) and type 2 diabetes (noninsulin-dependent diabetes mellitus).

Patients with type 1 diabetes cannot produce insulin, due to the lack of functions of the insulin-secreting beta cells in the pancreas (Meier et al. 2005). They must take insulin continuously every day to stay alive. Type 1 diabetes mostly affects children and adolescent patients, and it represents 5–10% of total diabetes cases worldwide. Patients with type 2 diabetes cannot produce sufficient insulin or cannot effectively metabolize it. This form of the disorder commonly affects elderly people and accounts for 90–95% of all diabetes cases (Hameed et al. 2015). People worldwide suffer from diabetes mellitus and 7% of the world’s adult population is affected by the disease (Philippe and Raccah 2009). In 2017, the largest number of diabetic patients, around 114 million, was recorded in China. Roughly 73 million diabetic patients were recorded in India, and 30 million were recorded in the United States. (https://www.statista.com/statistics/281082/countries-with-highest-number-ofdiabetics/).

There are many negative consequences for patients if diabetes remains untreated, such as blindness, kidney failure, depression, cardiovascular diseases, cancer and even death (Gerstein et al. 2011; Hansen et al. 2012; Huang et al. 2018). Retinopathy (damage of the retina, leading to blindness) and neuropathy (damage of the nervous system) are some of the most severe complications that have been attributed to diabetes (De Silva et al. 2012; Sobngwi et al. 2012).

Many Basidiomycota, such as Agaricus bisporus, Cyclocybe aegerita, C. cylindracea and Tremella fuciformis are used as medicine for the treatment or prophylaxis of type 2 diabetes. These mushrooms help patients avoid high levels of glucose because they contain the least amount of digestible carbohydrates in the diet (Poucheret et al. 2006). Bioactive metabolites, which are isolated from medical mushrooms and their cultured mycelia, act as biological antihyperglycemic agents in diabetes treatment (Table 1) (De Silva et al. 2012). Extracts of Inocutis levis (Hymenochaetaceae) have been reported to possess utility as a remedy for diabetes because they increase insulin resistance, insulin sensitivity and glucose uptake in tissues and hence help to control blood glucose levels (Ehsanifard et al. 2017). The fruiting bodies of Antrodia cinnamomea can be used to produce healthy foods and drugs that have anti-diabetes properties (Huang et al. 2018). Grifola frondosa has been used as medicine for type 2 diabetes, and its extracts can effect both hyperglycemia (when a high amount of glucose circulates in the blood) and hyperinsulinemia (when a high level of insulin circulates in the blood) (Poucheret et al. 2006).

Table 1 Anti-diabetic effects of some medical mushroom species

Fungal products are sold as remedies for diabetes. Ophiocordyceps sinensis capsules, SX-Fraction, ReishiMax capsules and Tremella are some of the examples of anti-diabetic products made with medicinal mushrooms (Li et al. 2004; De Silva et al. 2012) and is claimed to decrease fasting blood glucose levels in type 2 diabetes. This medicine can also be used to reduce blood pressure and body weight. SX-Fraction is considered a major alternative for enhancing insulin sensitivity (Preuss et al. 2007). Tremella is a medicinal product used in Chinese medicine; produced from Tremella fuciformis (silver ear mushroom/ white jelly leaf mushroom), it is mainly used for reducing blood glucose and cholesterol levels (Li et al. 2004).

Future investigation is needed to clarify the long-term effects of taking medicinal mushroom products with other drugs. It is necessary to justify the use of medicinal mushroom products as anti-diabetes (De Silva et al. 2012).

6. Improving nerve functioning

Human neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s disease, are disrupting neuronal populations in adults worldwide. The discovery and development of neuroactive compounds from medicinal mushrooms with the potential to improve nerve functioning has been extensively studied. Mushrooms, such as Antrodia camphorata, Ganoderma spp., Hericium erinaceus, Lignosus rhinocerotis and Pleurotus giganteus, have a long history of use in enhancing the peripheral nervous system. Nerve growth factors are important for the survival, maintenance, and regeneration of specific neuronal populations in the adult brain. It has been demonstrated that neurodegenerative diseases mostly occur because of the disappearance of nerve growth factors. Therefore, scientists have been attempting for over 20 years to discover fungi-derived neuroactive components which are able to cross the blood–brain barrier and induce the production of nerve growth factors.

Most of the potential neuroactive compounds, which may aid in the prevention or therapy of neurodegenerative diseases, have been discovered in Hericium erinaceus. This medical mushroom is known to produce two unique terpenoid classes, namely hericenones and erinacines, from its fruiting body and mycelia, which can stimulate synthesis of the nerve growth factor via the TrkA/Erk1/2 pathway. Not only does H. erinaceus induce nerve growth factors or nerve regeneration, but it has also been shown to improve digestive functioning and effect relief from gastritis while providing immune-support, such as anti-inflammatory and anti-oxidant activities. Several studies have demonstrated that hericenones such as hericenone A (19) and erinacines (erinacine C (20) (Fig. 6) induce the synthesis of nerve growth factors in vivo and in vitro (Thongbai et al. 2015). Wittstein et al. (2016) discovered corallocins A–C, a nerve growth and brain-derived neurotrophic factor inducing metabolites, from the related Hericium coralloides in cell based bioassays, while Rupcic et al. (2018) discovered two new erinacine derivatives from mycelial cultures of H. erinaceus and H. flagellum. Additional studies have revealed neuroactive activities in extracts from medicinal mushrooms that induce nerve growth factors, but the active principles remain to be identified. For instance, the aqueous sclerotium extract from the Malaysian medicinal mushroom, Lignosus rhinocerotis, contained neuroactive compounds that have been demonstrated to stimulate neurite outgrowth in vitro (Eik et al. 2012). Similarly, aqueous extracts of fruiting bodies of species referred to as “Ganoderma lucidum” (questionable identification because the report was from Asia where this species does not actually occur) and G. neo-japonicum were also effective at stimulating neurite outgrowth (Seow et al. 2013). Pleurotus giganteus was found to contain a high concentration of uridine, which has also shown nutritional outgrowth stimulatory effects (Phan et al. 2012). These results may give rise to a more systematic study of the phenomenon in the future.

Fig. 6
figure 6

Chemical structures of neurotrophic compounds from Hericium, as well as myriocin and its synthetic analogue fingolimod

The family Hericicaceae comprises other genera and species, such as Laxitextum incrustatum Mudalungu et al. (2016) and Dentipellis fragilis (Mitschke 2017), which were proven to contain compounds of the erinacine type; these cyathane terpenoids may constitute family-specific markers. On the other hand, Bai et al. (2015) have reported cyathane diterpenoids as nerve growth factor enhancers from cultures of a Cyathus species, and even the cyathanes from the fruit bodies of the mycorrhizal basidiomycetes of the genus Sarcodon seem to have similar effects (Cao et al. 2018). It should therefore be worthwhile to study genera that are known to produce cyathanes, as well as representatives of other mushroom genera related to Hericium, including Amylosporus and Wrightoporia, for such phenomena. This examination may lead to the discovery of additional novel neurotropic compounds. Reliable screening systems as well as genetic models of human neurodegenerative diseases are now available for in vivo cell biological analysis of disease progression and intervention.

While the mode of action of the hericenones, corallocins and erinacines remains to be clarified, a very important drug that constitutes a mimetic of a fungal metabolite should be mentioned in this context. Fingolimod (21) is a product of total synthesis that has been discovered during the course of a mimetic synthesis program that used as template myriocin (22), a compound produced by the insect associated ascomycete Isaria sinclairii (Strader et al. 2011) (Fig. 6). Fingolimod (sold under the brand Gilenya), is a potent immunosuppressant that was approved in 2010 by the U.S. Federal Drug Association as a new treatment for multiple sclerosis. Fingolimod is phosphorylated in vivo by sphingosine kinase 2, and the resulting metabolite binds to the extracellular G protein-coupled receptors, sphingosine 1-phosphates. This prevents the release of lymphocytes from lymphoid tissue and therefore can suppress the immune system. Aside from its proven effects against the symptoms of multiple sclerosis, the compound can also potentially be used in the therapy of cancer and during organ transplants. Likewise, additional potential usages for the erinacines and hericenones may become conceivable once the biochemical and molecular mechanisms by which they exert their activities in biological systems have been elucidated.

7. Fungi in Traditional Chinese Medicine

Traditional Chinese Medicine (TCM) has been used for thousands of years, during which time traditional knowledge originating in ancient China has been gradually developed further and distributed to Japan and other Asian countries. TCM relies heavily on the use of natural remedies including plants, animals, and even minerals to cure various diseases. However, in spite of the fact that the term “herbal medicine” is widely used to describe TCM and other ethnobotanical approaches for disease therapy, several mushrooms are commonly used as important ingredients. Furthermore, since fungal taxonomy has yet to be globally harmonized, there is considerable confusion concerning the identity of these important traditional “herbal” remedies. A compilation of the most important TCM mushrooms is therefore provided in Table 2, and we will henceforth refer to the species according to their scientific names as given in this table, regardless of whether they have been or are still being referred to by incorrect or ambiguous names. For instance, we will refer to “Ganoderma lucidum” as G. lingzhi, regardless of whether the authors of the respective cited papers had already adopted the modern taxonomy.

Table 2 The correct scientific terminology of some important medicinal mushrooms used in traditional Chinese medicine

TCM has evolved through a combination of theory and practical experience of Chinese healers over many centuries. The first recorded use of Chinese medicine was during the Shang Dynasty in the eleventh century BC (1100–1001 BC), where even Ganoderma was recorded in detail and for the first time. However, the first comprehensive description of Chinese herbal remedies and their medicinal value was published in “Shennong Bencaojing (神农本草经),” during the Han dynasty (206 BC-220 AD). Later, another very comprehensive account of Chinese herbology, known as the “Bencao Gangmu (本草纲目)” or “Compendium of Materia Medica” (Sanodiya et al. 2009) was compiled by Li Shizhen (1518 ~ 1593) during the Ming Dynasty (1368–1644). In 1987, Chinese scientists compiled a list of 272 medicinal mushroom species (Ying et al. 1987). Later, this number increased to 799 species, 500 thereof with antitumor effects (Wu et al. 2013), and we estimate that about 850 species are presently being used as remedies in China. TCM has adopted a more holistic philosophy when compared with Western medicine (Wang et al. 2017). Chinese medicinal mushrooms have been used since the beginning of human history as a “protector herb” in order to maintain and enhance good health.

Whereas the majority of the TCM ingredients are derived from plants, several macrofungi have been included in the formulas. Some macrofungi are frequently included in TCM medicine formulas and are also very commonly sold in the medicinal or local markets (Fig. 7). The most important species and species groups are compiled in Table 2. Notably, some, such as Ganoderma lingzhi and Wolfiporia cocos, are very expensive, while others such as Ophiocordyceps sinensis have become rare in nature (Sung et al. 2007; Zhang et al. 2012; Xiang et al. 2014; Hapuarachchi et al. 2018, 2019).

Fig. 7
figure 7

Different dried Ganoderma products sold in a Traditional Chinese Medicine pharmacy market, Kunming Province, China

Ganoderma lingzhi (Lingzhi) contains both complex, high and low molecular weight natural bioactive compounds, which are mostly triterpenoids (Sandargo et al. 2019a). Bioactive compounds have shown in vitro activities against cancer cells, although none have been regarded as effective enough to enter clinical development as an ethical anticancer drug. Extracts of mycelial cultures and fruiting bodies of Ophiocordyceps sinensis and Cordyceps militaris primarily contain cordycepin, a derivative of nucleoside adenosine, with dimethylguanosine and iso-sinensetin, and showed moderate anticancer and antiproliferative effects in vitro (Wong et al. 2010). Several bioactive compounds derived from mushrooms used in TCM were identified by bioactivity-guided fractionation. On the other hand, the potential therapeutic value of these fungal TCM products for the treatment of various diseases (e.g. cancer, diabetes, cardiovascular and neurodegenerative diseases) is even supported by clinical studies (Table 3).

Table 3 Some important medicinal mushrooms used in traditional Chinese medicine

There has been intensive debate over the utility of TCM for modern healthcare. Many clinical scientists have doubted the utility of the classical TCM remedies because of their inaccurate descriptions, as well as the different philosophies regarding their therapeutic application. In fact, therapy for diseases in the Western world is mainly based on the application of single substances that have strong and selective biological and pharmacological activities, and must undergo very thorough clinical trials before they can be applied as therapeutic drugs. TCM, by contrast, often uses mixtures of preparations made from several plants, fungi and other organisms, each of which may contain dozens if not hundreds of different compounds. Therefore TCM does not really fit into the modern healthcare system (Fu and Yu 2005). However, the example of artimisinin shows that compounds from TCM can be very useful as remedies for diseases that have an unmet medical need. This terpenoid was originally found in the asteraceous traditional Chinese medicine plant Artemisia annua; a semisynthetic derivative, artesunate, is now on the market as a last generation antimalaria drug (the inventor received the Nobel Prize for Medicine in 2015). This example shows that it is worthwhile to study the ingredients of traditional Chinese medicine plants using modern drug research methods in order to discover novel therapeutic agents. Several examples of beneficial compounds from mushrooms have found their way into exploratory drug research projects (Grothe et al. 2011).

In addition, the recent integration of TCM and modern medicine has begun to solve multiple worldwide health problems. Many databases were evaluated to advance scientific formulations, chemical analysis, potential approaches, and other health targets. The World Health Organization (WHO) has also released a standard series for developing traditional medicines across the world, including medicinal mushrooms (Tang et al. 2018). The discovery of biologically active compounds from medicinal mushrooms can impact the direction of future medical development, and also has broad market prospects in North America, Europe and other developed economies (Lee et al. 2012; Wang et al. 2017). This may also increase international exchange, leading to the unprecedented development of Chinese medicine in the western world (Zhu 2018).

Chinese medicines have been utilized within several alternative medicinal practices to introduce positive changes in order to provide better contributions for health care while developing future medicinal products for diseases and for use in therapy (Lin et al. 2015; Han et al. 2017). However, there are challenges to the development of TCM products, due in part to the nature of the therapeutic potential and the fact that the mechanisms of action are often unclear. Furthermore, the materials used often do not meet the requirements of quality control and standardisation (Wen et al. 2017), and hence they are difficult to register as prescription drugs. Many materials have not been tested thoroughly to the standards of western medicine and can therefore only be sold as over-the-counter drugs or even neutraceuticals. Many challenges still stand in the way towards international collaborative exchange for opportunities to develop TCM, thereby advancing it at the global level (Chen et al. 2016). The use of mushrooms is advantageous when compared with the plants used in TCM, since mushrooms can be produced biotechnologically under controlled conditions and with standards, making them easier to work with than species that have to be grown and harvested in nature. In conclusion, to achieve the global acceptance of TCM products, it will be necessary to conduct clinical trials based on high quality standardised materials.

8. Cardiovascular disease control by fungi

Cardiovascular diseases include diseases of the heart, vascular diseases of the brain, and diseases of blood vessels (Mendis et al. 2011). Elevated levels of plasma cholesterol are responsible for these diseases, as they play a major role in atherosclerosis, the clogging or hardening of arteries caused by accumulations of fatty deposits (usually cholesterol) (Miller 2001). These diseases were responsible for 17.3 million deaths per year in 2015, and are the leading source of deaths worldwide (GBD 2015). Inhibition of de novo synthesis of cholesterol was demonstrated to be an effective method for reducing plasma cholesterol levels (Miller 2001). The rate determining step is the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate by HMG-CoA reductase; hence selective inhibition of the latter enzyme, can reduce the synthesis of cholesterol (Brown et al. 1976; Endo et al. 1976). The most important class of HMG-CoA reductase inhibitors are the statins (Fig. 8), which are derived from fungal natural products and contain two types of structures moieties, a hexahydro-naphthalene system and a β-hydroxylactone system. The statins are also the best-selling class of pharmaceutical drugs, with an annual turnover in the range of US$50 billion. Therefore, the most important compounds of this type are treated here.

Fig. 8
figure 8

Chemical structures of statins with cholesterol-lowering properties

Brown et al. (1978) isolated compactin (22) (also known as mevastatin and ML-236B) from Penicillium brevicompactum as an antibiotic, but its hypocholesterolemic activity was later revealed by Endo et al. (1976), who used the name “ML-236B”. Later another HMG-CoA reductase inhibitor named mevinolin (23) was isolated from Aspergillus terreus by Alberts et al. (1980). The first statin drug approved by the United States Food and Drug Administration was lovastatin (24) in 1987 (Jahromi et al. 2012). Although lovastatin is produced by several species of Penicillium (Endo et al. 1976), Monascus species (Miyake et al. 2006; Sayyad et al. 2007), Doratomyces, Gymnoascus, Hypomyces, Phoma and Trichoderma, the commercialized product is derived from Aspergillus terreus (Jahromi et al. 2012). Another statin containing a product called Xuezhikang or “red yeast rice extract”, produced by the fermentation of Monascus spp., has been widely used in China for centuries for treating circulatory disorders. The low density lipoprotein lowering ability of “red yeast rice extract” is clinically proven and contains lovastatin (Lu et al. 2008).

Solid state fermentation, or submerged cultures, can be used for the production of lovastatin (Ruddiman and Thomson 2001; Lai et al. 2003; Suryanarayan 2003; Wei et al. 2007; Jaivel and Marimuthu 2010; Pansuriya and Singhal 2010; Jahromi et al. 2012), but production is significantly higher in the former (Jaivel and Marimuthu 2010; Jahromi et al. 2012). Sorghum grain, wheat bran, rice and corn are used as substrates for solid state fermentation (Wei et al. 2007; Jaivel and Marimuthu 2010; Jahromi et al. 2012).

Basidiomycetes are a good source of nutrient supplement for humans. Certain molecules in mushrooms can modify cholesterol absorption, metabolism, and also modulate the gene expression related to cholesterol homeostasis (Gil-Ramírez et al. 2016). Grifola frondosa, Hypsizigus marmoreus and Pleurotus ostreatus were able to differentially modulate the gene expression patterns of mice livers (Gil-Ramírez et al. 2016). Of the biologically active compounds from fungi that can reduce the amounts of cholesterol in the blood, the most studied are ergosterol derivatives (Gil-Ramírez et al. 2016). The cholesterol-lowering properties are mainly caused by the structural similarity with cholesterol (Gil-Ramírez et al. 2016). Further, the biological activity of β-glucans and chitin may be due to their binding abilities to cholesterol receptors (Gil-Ramírez et al. 2016).

Francia et al. (1999) recorded 16 species of edible mushrooms with biological activities against cardiovascular disease. Species of the genera Auricularia (Fan et al. 1989), Ganoderma (Kabir et al. 1988), Grifola (Kubo and Namba 1997), Pleurotus (Bobeck et al. 1991) and Tremella (Cheung 1996) have been reported to contain cholesterol-lowering compounds. Ophiocordyceps sinensis has also been shown to reduce total cholesterol levels, which has been attributed to the fact that it contains polysaccharide “CS-F30” composed of galactose, glucose and mannose (Kiho et al. 1996). For instance, low density lipoprotein cholesterol levels were reported to be reduced by Auricularia auricula-judae (Fan et al. 1989) and Tremella fuciformis (Cheung 1996), and triglyceride levels were reported to be reduced by Grifola frondosa (Kubo and Namba 1997), Lentinula edodes (Kabir and Kimura 1989) and Ophiocordyceps sinensis (Kiho et al. 1996).

9. Antiviral agents

Health and mortality-debilitating diseases caused by viruses continue to cause serious global epidemics, especially in cases where vaccines and antiviral chemotherapies are insufficient or not available. The current state of virus-related pandemics is also significantly limiting drug efficacy by the emergence of drug-resistant strains. Hence, there is an urgent need to identify and develop natural product-inspired drug leads that could help control viral infections. A plethora of potentially active natural products have been isolated from fungi and screened for antiviral activity, even though none of them has reached the market yet. This entry focuses on natural products exhibiting potent activity on selected human pathogenic viruses, such as the human immunodeficiency virus (HIV), influenza virus, herpes simplex virus (HSV), hepatitis virus and other human pathogenic viruses such as enterovirus-71, and respiratory syncytial virus (RSV).


Human Immunodeficiency Virus (HIV) inhibitory natural products from fungi

A comprehensive review of the literature identifies three main targets for anti-HIV drug discovery: virus entry, reverse transcription and integration.

The entry of HIV involves interactions with proteins and is a target for the discovery of new viral entry blockers. Examples of a few discoveries are provided. A bis-indolyl quinone, hinnuliquinone (25) (Fig. 9) from an unknown fungus isolated from Quercus coccifera, inhibited wild-type and clinically-resistant HIV-1 protease. HIV-1 protease is a key enzyme involved in the replication and maturation of the HIV-1 virus (Singh et al. 2004). Altertoxins I–III and V, oxidized perylenes from Alternaria tenuissima, inhibited HIV-1 replication at micromolar concentrations (Bashyal et al. 2014). The dimeric tetrahydroxanthone, penicillixanthone A from Aspergillus fumigatus displayed strong anti-HIV activity by inhibiting CCR5-tropic HIV-1 SF162 and CXCR4-tropic HIV NL4-3 (Tan et al. 2017). A marine-derived A. niger produced malformin C, which exhibited a very strong anti-HIV-1 activity (Zhou et al. 2015a). An endophytic Aspergillus sp. CPCC 400735 produced three phenalone and cytochalasin derivatives also showing anti-HIV activity (Pang et al. 2017). Concentricolide from “Daldinia concentrica” (taxonomy doubtful since this species does not occur in China according to the world monograph by Stadler et al. 2014) inhibited HIV-1 by induction of cytopathic effects (Fang and Liu 2009). Novel sesquiterpenoids from Paraconiothyrium brasiliense showed moderate anti-HIV-1 replication in C8166 cells (Liu et al. 2010b). The pupukeanane sesquiterpenoid chloropupukeannolide A from Pestalotiopsis fici showed significant anti-HIV-1 activity (Liu et al. 2010c). The cytochalasan perconiasin J and the meroterpenoid periconone B from Periconia sp. displayed moderate anti-HIV activity (Liu et al. 2016, 2017b). The farnesylated isoindolinones stachybotrysams A–C and the phenylspirodrimane derivatives stachbotrysin A and G from Stachybotrys chartatum displayed moderate anti-HIV activity (Zhao et al. 2017a, b).

Fig. 9
figure 9

Chemical structures of fungal metabolites that were reported to possess antiviral activities

The three consecutive functions controlled by HIV reverse transcriptase are: RNA reverse transcription to DNA, degradation of RNA template by RNase H, and duplication of the remaining DNA strand. Inhibition of these processes is important for the discovery of anti-HIV drugs. Stachybosin D (26) (Fig. 9), a phenylspirodrimane metabolite from a sponge-derived isolate of Stachybotrys chartarum, showed inhibitory effects on HIV-1 replication by targeting reverse transcriptase. It was able to inhibit NNRTIs-resistant strains and wild-type HIV-1 (Ma et al. 2013).

Integrase is the only protein encoded by HIV-1, aside from the enzymes protease and reverse transcriptase. Singh et al. (1998, 2002a, b, 2003a, b, c) described several compounds with inhibitory activity against integrase from various fungal species. Accordingly, equisetin and phomasetin from Fusarium heterosporum and Phoma sp., respectively Singh et al. 1998); integracins (Integrastatin A (27)) from Cytonaema sp. (Singh et al. 2002a); integrastatins (from an unidentified fungus; cf. Singh et al. 2002b); epiphiobolins C and K from “Neosartorya”; i.e., Aspergillus sp.; 8-O-methylanthragallol from Cylindrocarpon ianthothele; hispidin and caffeic acid from Inonotus tamaricis; 3-hydroxyterphenyllin from Aspergillus candidus (Singh et al. 2003a); naphtho-γ-pyrones from Fusarium sp. (Singh et al. 2003b); and xanthoviridicatins from Penicillium chrysogenum (Singh et al. 2003c) all showed low micromolar inhibition against the cleavage reaction of HIV integrase. Funalenone from Penicillium sp. FKI-1463 also had the same effect (Shiomi et al. 2005).


Influenza virus inhibitory natural products from fungi

The H1N1 and H3N2 viruses are among the targets of natural products of fungal origin with anti-influenza activity. The terpenoid stachyflin (28), isolated from a marine-derived isolate of Stachybotrys showed modest activity against the influenza A virus (H1N1) with an IC50 of 3 × 10−3 µM (Minagawa et al. 2002). The γ-pyrone isoasteltoxin from Aspergillus ochraceopetaliformis showed low micromolar activity (IC50 = 0.23 µM) against both influenza viruses (Wang et al. 2016). Another Aspergillus sp., strain produced the γ-pyrone derivative asteltoxin E with IC50 values of 6.2 and 3.5 µM against H1N1 and H3N2, respectively (Tian et al. 2016). 3β-Hydroxysterol from Pestalotiopsis sp. (Sun et al. 2014) and chermesinone from Nigrospora sp. (Zhang et al. 2016b) also had moderate inhibitory effects. Aureonitol, a metabolite of Gliocladium spp. inhibited influenza A and B virus replication with an EC50 of 100 nM against H3N2 via suppression of influenza hemagglutination, while significantly impairing viral adsorption (Sacramento et al. 2015).


Herpes Simplex virus (HSV) inhibitory natural products from fungi

The impotant human pathogenic viruses HSV-1 and HSV-2 were also subject of sceening programs of fungal metabolite libraries, even though up to date no drug could be discovered that would match the activity of the market standard. Coccoquinone, an anthraquinone from Aspergillus versicolor, demonstrated an IC50 of 3 µM against HSV-1 (Huang et al. 2017a, b). Five lipopeptides from the marine-derived fungus Scytalidium sp. showed moderate anti-HSV-1 and anti-HSV-2 activities in a dose- and time-dependent pattern (Rowley et al. 2003). The diphenyl ether glycoside cordyol C from Cordyceps sp. BCC 186 exhibited significant anti-HSV-1 activity with an IC50 value of 1.3 μg/ml (Bunyapaiboonsri et al. 2011).


Hepatitis virus inhibitory natural products from fungi

One novel tricyclic polyketide derived from a collection of fungal-derived compounds, vanitaracin A (29), was reported to inhibit viral entry process with an IC50 value of 0.6 µM and good selectivity. It was observed to directly interact with the HBV entry receptor correlated to hepatitis D virus and impaired viral bile acid transport pathway. This compound also inhibited all HBV genotypes (A–D) (Kaneko et al. 2015). The anthraquinone metabolite, 2′R-1-hydroxyisorhodoptilonmetrin, showed better anti-hepatitis B virus activity as compared to the positive drug control, lamivudine (Jin et al. 2018). The epipolythiodioxopiperazine derivative, 11′-deoxyverticillin A, showed antiviral activity by decreasing HBV-X replication through inhibition of Akt activity or depletion of the autophagic genes, LC3 and p62 (Wu et al. 2015a). Sandargo et al. (2018) and Narmani et al. (2019) have recently discovered additional anti-HCV agents like 4-hydroxypleurogrisein (30) from the nematode trapping basidiomycete Hohenbuehelia grisea and cytosporaquinone B (31) from an Iranian phytopathogen belonging to the genus Cytospora. Recently Sandargo et al. (2019b) reported the meroterpenoid rhodatin (32) from cultures of the rare basidiomycete Rhodotus palmatus and also found significant anti-HCV activities for this compound, which features a new carbon skeleton.

In view of the fact that newly arising viral diseases are steadily being reported and they can spread more easily due to gflobalization effects, the search for novel antiviral agents is as of recently gaining importance. Some of the natural products pointed out in this entry may potentially find their way to antiviral drug development in the future. However, the discovery of new chemical derivatives with nanomolar activity and high selectivity indices is still warranted.

10. Immunosuppressive and immunomodulatory agents from fungi

Immunosuppression is a form of therapy that prevents the immune system of patients from acting against transplanted tissues and organs; without the availability of immunosuppressive drugs, the progresses made in modern medicine, in particular regarding kidney, heart and liver transplants, would be unthinkable. Furthermore, immunosuppressants are used to control severe manifestations of allergic and autoimmune related diseases. Many of these drugs specifically address certain biochemical pathways that are crucial for the functioning of human defense against alien organisms, such as pathogens, by selectively inhibiting the immunocompetent lymphocytes or signal transduction cascades that regulate the transcription of cytokines. For this reason, patients treated with immunosuppressants often have to be hospitalized and treated in parallel with antibiotics to prevent infection.

Some of the most important immunosuppressive drugs are natural products that are being produced biotechnologically by fermentation of bacteria and fungi. While tacrolimus and sirolimus are derived from actinobacteria and will accordingly not be treated here, cyclosporine (35) and mycophenolate mofetil (33) are fungal metabolites, and the present entry is therefore dedicated to these important molecules (Fig. 10).

Fig. 10
figure 10

Chemical structures of immunosuppressive drugs derived from fungal fermentation

Mycophenolic acid (34) (Fig. 10) was the first antibiotic discovered and isolated in crystalline form from fungi, contrary to what is written elsewhere in the literature, where the penicillins are often regarded as the oldest natural antibiotics. Biogenetically, this compound is a meroterpenoid, produced by Penicillium species, including P. brevicompactum and P. roquefortii, and its biosynthesis has recently been elucidated in the latter species (Del-Cid et al. 2016). For various reasons, the compound never made it into clinical development as an antibacterial or antifungal agent (Bentley 2000; Bills and Gloer 2016). Ultimately, its utility as an immunosuppressant became evident, and it is now the active principle of several marketed drugs, such as Myfortic® and CellCept®. The compound selectively inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme that is crucial for the biosynthesis of guanosine nucleotides in mammalian cells. As this enzyme is more essential in the T- and B-lymphocytes than in other cell types, and its isoform in the lymphocytes is more sensitive to mycophenolic acid, the drug has a more potent cytostatic effect on lymphocytes than on other cell types, and thereby suppresses the immune system (Allison and Eugui 2000). Another secondary beneficial effect of mycophenolíc acid is the depletion of tetrahydrobiopterin, which is a co-factor for the inducible nitric oxide synthase (iNOS). Consequently, the administration of mycophenolic acid prevents damage of tissues mediated by peroxynitrite. The drug is mainly being used to prevent organ rejection following transplants, as well as in the therapy of psoriasis (Epinette et al. 1987) and other immunological disorders.

Cyclosporine A (35) (Fig. 10) was first discovered as a mildy active antifungal antibiotic by Dreyfuss et al. (1996), who also gave the first hints as to its immunomodulatory activity. The compound is a nonribosomally biosynthesized peptide derived from fermentation of the ascomycete Tolypocladium inflatum, and its biosynthetic gene cluster was recently elucidated by Bushley et al. (2013). After years of intensive research, it was found that this cyclopeptide has a highly specific biochemical mode of action as it selectively binds to cyclophilin A. This protein is an inhibitor of calcineurin, which is responsible for activation of transcription of the cytokine, interleukine 2. If interleukine 2 is depleted, the immune response of the human body will be suppressed and rejection of transplants can be prevented (Green et al. 1981; Wiesinger and Borel 1980). Therefore, cyclosporine A has become the active ingredient of blockbuster drugs, such as Sandimmune®, Neoral® and Restasis®). In addition to organ transplants, such immunosuppressants can be very useful in the therapy of other diseases, including allergies and neurodegeneration. An example for the latter indication is the synthetic drug, fingolimod (Gilenya®; 21 in Fig. 6), which is described further above in chapter 6.

In this context, it is worthwhile to note that many fungal metabolites are highly useful in therapy because they show the opposite activities in biological systems, i.e., they boost the immune system and therefore increase the resistance against pathogens or even help to prevent cancer. Striking examples for such molecules are the β-glucanes and protein–polysaccharide complexes that are being treated elsewhere herein.

Strategies against plant disease

Fungi are important agents in combating various fungal pests and plant diseases found in greenhouses, the field, and even post-harvest. Fungi also have the potential to be used against certain animal parasites, such as nematodes. In this section, we discuss how fungi are being used to control plant disease, pests, nematodes, and herbicides, as well as their possible future applications.

11. Biocontrol of plant disease using endophytes

Fungal pathogens are the chief agent of plant disease, effecting severe agricultural losses worldwide (Hyde et al. 2014; Punja and Raj 2003; Strange and Scott 2005; Horbach et al. 2011). Agrochemicals play a significant role in plant disease management and ensure sustainable and productive agriculture systems. However, the intensive use of chemicals (determined by frequent and high dose of pesticides) has adverse effects on human health, ecosystem functioning, and agricultural sustainability (Anderson et al. 2004; Vinale et al. 2008; Suryanarayanan et al. 2016). Biocontrol is a strategy used to control plant pathogens, resulting in minimal impact to the environment (De Waard et al. 1993; Vinale et al. 2008).

Endophytes reside asymptomatically within a plant for at least part of their life cycle (Carrol 1998; Huang et al. 2009; Sun et al. 2011; Clay et al. 2016). Fungal endophytes can be broadly classified into two groups, the clavicipitaceous (C) and the non-clavicipitaceous (NC). These endophytes are classified based on evolutionary relatedness, taxonomy, host plant range and ecological function (Hyde and Soytong 2008; Rodriguez et al. 2009; O’Hanlon et al. 2012; Santangelo et al. 2015). Clavicipitaceous endophytes, including Atkinsonella, Balansia, Balansiopsis, Echinodothis, Epichloë, Myriogenospora and Paraepichloë species are commonly associated with grasses in the family Poaceae and rely on their host throughout their life cycle as mutualist species (Rodriguez et al. 2009; Purahong and Hyde 2011; O’Hanlon et al. 2012; De Silva et al. 2016). Non-clavicipitaceous endophytes, such as Fusarium sp., Colletotrichum sp., Phomopsis sp. and Xylaria sp. are found in most terrestrial plants, and might not inhabit the host plants for their entire life cycle (Rodriguez et al. 2009; Delaye et al. 2013; De Silva et al. 2016; Jayawardena et al. 2016).

Endophytes are neutral or beneficial to their plant hosts (Backman and Sikora 2008). They boost host plant growth, fitness, stress tolerance, and alter interactions with pests and pathogens (Oono et al. 2015; Clay et al. 2016). Endophytes also provide protection against herbivory (O’Hanlon et al. 2012; Santangelo et al. 2015). More importantly, endophytes have potential as an unexplored source of candidate strains for potential biocontrol applications (Ek-Ramos et al. 2013; Oono et al. 2015). For example, endophytic Ampelomyces species parasitize powdery mildews (Busby et al. 2016). Since powdery mildews are biotrophs, their antagonists act mainly through antibiosis and mycoparasitism (Busby et al. 2016).

Biocontrol strategies utilize antagonistic mechanisms to disrupt the life cycle of pathogens (cf. Fig. 11), leading to the prevention of infection, reduction in colonization of host tissues, reductions in sporulation, and affecting the pathogen’s ability to survive (Punja and Raj 2003; Busby et al. 2016). The hyperparasitic antagonism may be mediated by factors such as include the as production of lytic enzymes and/or antibiotics, while other biocontrol agents may induce the host plant’s defense or just compete with the pathogen for nutrients and ecological niches (Yan et al. 2015; Busby et al. 2016; Lecomte et al. 2016; Schlegel et al. 2016).

Fig. 11
figure 11

Methodology used to assess biocontrol activity of endophytes against pathogens in cocoa plants

Mejía et al. (2008) studied endophytes within the healthy leaves of Theobroma cacao, as well as their antagonism against the pathogenic Basidiomycota species Moniliophthora perniciosa (witches broom), Moniliophthora roreri (frosty pod rot) and the oomycete Phytophthora palmivora (black pod rot). The results showed that two endophytes, identfied as Colletotrichum gloeosporioides and Clonostachys rosea, respectively, decreased pod loss due to black pod rot, and reduced sporulating lesions in cacao pods caused by Moniliophthora roreri.

Endophytic fungi from various host plants have been shown to be effective biocontrol agents, including Alternaria sp. and Cladosporium sp., isolated from wheat (Huang et al. 2016), and Alternaria alternata, isolated from grapevine leaves (Zhang et al. 2017b). The use of antagonistic endophytes as biocontrol agents, such as Trichoderma and Chaetomium, present an attractive option for management of certain plant diseases. It is important to screen potential endophytes through in-vitro experiments following field experiments under different environment conditions. In future research using molecular technologies (e.g., metagenomics), ecological dynamics are essential to developing commercial biocontrol agents, as these contribute to sustainable agriculture. It is critical to note that the species isolated as endophytes from a certain host plant may be pathogenic to other plants. Moreover, a careful risk assessment that excludes the possibility for the overproduction of mycotoxins is a mandatory prerequisite for registrations of new biocontrol agents, regardless of whether the producer organisms are endophytes.

12. Biocontrol of insects using fungi

The loss in productivity due to crop damage from insects represents a serious threat to the agricultural sector. The global crop loss due to insects contributed to losses of almost $470 billion each year (Culliney 2014), with the global expenditures on pesticides being in the range of $56 billion in 2012. Strikingly, of the $56 billion, only $2–3 billion was spent on biopesticides (Marrone 2014). In the USA, insecticides contributed to almost 14% of all pesticide expenditures (Sabarwal et al. 2018).

The most common strategy for controlling insect invasions is the use of synthetic chemical pesticides, such as Chlorpyrifos, Acephate and Bifenthrin (Dai et al. 2019a). However, insecticidal resistance has become an undeniable phenomenon, and has led to the disastrous collapse of the pest control in many countries (Naqqash et al. 2016). There are also other concerns arising regarding the use of these synthetic chemicals, namely with food safety, adverse effects to non-target organisms—especially those beneficial antagonists of insects—and the environmental impact associated with the use of harmful chemical compounds (Sandhu et al. 2017). The drawbacks to conventional insecticides spurred the search for potent and eco-friendly biocontrol agents.

Biological control agents offer more advantages than their chemical counterparts, since they are safe for other non-target organisms and infect only specific species, with long-term results on target pests (Sanda and Sunusi 2016). In particular, the entomopathogenic fungi, have the capacity to reduce or eradicate insect populations. Most fungi used for the control of insect pests are ascomycetes, which are usually found in the soil and can cause natural outbreaks on their own when environmental conditions are favorable. Some fungal strains have been developed into commercial products because of their ability to be mass produced (e.g. Beauveria bassiana, Lecanicillium muscarium, Metarhizium anisopliae). These can infect a wide range of insect hosts. (cf. Fig. 12). Specific fungal strains in commercial products target insect groups such as Coleoptera, Diptera, Hemiptera, Hymenoptera, Lepidoptera and Orthoptera (Dauda et al. 2018).

Fig. 12
figure 12

Entomopathogens infecting insect hosts. aAcrodontium crateriforme, bCordyceps militaris, cOphiocordyceps nutans

Some entomopathogenic fungi can also exist as plant endophytes in a variety of hosts. They can exhibit dual functions, acting against insects and plant pathogens, thus giving protection to plant hosts. Moreover, they can have additional roles in endophytism, plant disease antagonism, growth promotion and rhizosphere colonization (Yun et al. 2017; Jaber and Ownley 2018).

Generally, the first mode of action of entomopathogenic fungi is to produce sticky spores to insure adhesion to the body of the host. The non-specific adhesion mechanism of the conidia is due to their hydrophobic properties, which has protein interactions with the hydrophobic exoskeleton of the susceptible host. The spores germinate quickly and initiate penetration of the insect exoskeleton. The fungal cells multiply in the hemocoel of the host’s body, increasing the turgor pressure and eventually killing the insect. The entomopathogen grows in the host’s cadaver to optimize spore production and dispersal under favorable environmental conditions (Roy et al. 2006). High numbers of spores are required to insure infection, with a minimum of 1 × 108 to 1 × 109 conidia/ml (Inglis et al. 2012).

Entomopathogenic fungi also produce secondary metabolites that can act as toxins with insecticidal effects. Proliferating protoplasts produce these compounds to weaken the host’s defense mechanisms, causing rapid death (Hussain et al. 2014). The entomopathogens that produce toxins are more effective at killing the insect hosts as compared with those strains that do not produce such metabolites (Kershaw et al. 1999). There are a variety of active compounds produced by entomopathogenic fungi that exhibit insecticidal properties, as listed in Table 4. Beauvericin (36 in Fig. 13) is a well-known active compound produced by entomopathogenic fungi. It plays a key role in the virulence of fungi that infect arthropods (Rohlfs and Churchill 2011). It is a cyclic hexadepsipeptide, containing three D-hydroxyisovaleryl and three N-methylphenylalanyl residues in alternating sequence, and belongs to the enniatin antibiotic family. It is structurally similar to enniatins; however, it differs in the nature of its N-methylamino acid (Wang and Xu 2012). It was first isolated from Beauveria bassiana (Hamill et al. 1969) and later from Fusarium species (Liuzzi et al. 2017). Beauvericin has a strong insecticidal function against a broad spectrum of insects. Since the target insects are moving organisms, the entomopathogenic fungi producing beauvericin are more effective insecticidal agents than the direct use of the compound. Beauvericin was first discovered to have insecticidal activity by Hamill et al. (1969). Other studies proved the efficacy of beauvericin in killing other insects, such as Calliphora erythrocephala, Lygus spp. (Leland et al. 2005), Aedes aegyptii (Grove and Pople 1980), Spodoptera frugiperda and Schizaphis graminum (Ganassi et al. 2002); however, it can also be toxic to bees, thus posing a threat to other beneficial insects when applied in the field.

Table 4 Some insecticidal compounds produced by entomopathogenic fungi
Fig. 13
figure 13

Chemical structures of insecticidal compounds from fungi

Bassianolide (37) a cyclic depsipeptide from Lecanicilium lecanii, exhibits moderate cytotoxicity and an immunosuppressive effect to insect hosts. It can cause significant maximum mortality to Plutella xylostella at 0.5 mg/ml concentrations (Keppanan et al. 2018). As in other groups of fungal cyclopeptides, several variants if bassianolies are known (Matsuda et al. 2004).

Destruxins (38–40), the cyclic hexadepsipeptide mycotoxins are produced by Metarhizium anisopliae. They can kill a variety of insect pests. The purified destruxins can cause toxic effects on the larval developmental stage of mosquitoes (Aedes aegyptii) with high mortality rates (Ravindran et al. 2016). The study of Dong et al. (2016) also revealed positive correlations between destruxin production and blastospore formation, and the producer strain has the potential to be developed into a mycoinsecticide.

Enniatins (4144) are only produced by Fusarium species. They act as ionophores that bind with ammonium in the transport of ions in the lipid bilayer membrane of the cell. This ionophoric property of enniatins leads to the toxic action in the cell through the disturbance of the normal physiological concentration. Their best studied derivative, Enniatin B was previously shown to exhibit insecticidal activity against blowfly (Calliphora erythrocephala) and mosquito larvae (Aedes aegypti) (Grove and Pople 1980).

The successful application of entomopathogenic fungal strains relies on several factors, such as level of virulence, production efficiency and level of safety to humans and other non-target species. Virulence depends on a complex of factors, such as spore hydrophobicity, which is involved in the conidial adhesion, germination polarity of the spores wherein unidirectional spores are more virulent than multi-directional ones, presence of hydrolytic enzymes to breach the host’s defense wall, and sensitivity to abiotic factors like temperature and humidity. Moreover, entomopathogenic fungi should only be considered for commercialization if they demonstrate high production efficiency, wherein the strains have minimum requirements for growth and can be grown and mass produced in solid substrate (Hussain et al. 2014), thus reducing production costs.

Certain techniques should be considered in order to increase the effectiveness of mycoinsecticides. Since insect larvae usually embed themselves into plant tissues or soil and do not feed on crops (Hall 1998), they do not typically stay in a specific location and therefore are very difficult to target. Spray application can be inefficient at this stage and depositing mycoinsectides over a field or crop may not be effective. Therefore, granular formulations which coat dry spores onto bran or grains, or the drying and fragmentation of mycelium to hold spores in starch, can both be effective methods to treat insects in the field (Hall 1998). Adding the granular substances to mycoinsecticides increases the accuracy and efficiency of the spray.

Several tactics have been identified by Lacey and Kaya (2007) to increase the effectiveness of mycoinsecticides. Preventive applications could be inefficient because the residues are not long-lasting, and therefore they should be applied only when the target pest is seen. Mycoinsecticides should be applied before the pest population reaches peak numbers, and therefore early application is essential. Timing is also important: identifying the life cycle of the host, which has a higher probability of being in contact with the spores, could also increase the effectiveness of the mycoinsecticide. For example, Beauveria bassiana is more efficient in infecting active nymphs than winged adults. Moreover, mycoinsecticides should not be applied during droughts because the environmental conditions are not favorable for the germination of the spores.

Approximately 750 fungal species have been identified as insect pathogens; however, in 1998 only 12 species were utilized as mycoinsecticides in insect sprays (Wraight and Carruthers 1998). By 2007 the number of mycoinsecticides had increased to about 110 commercially available products in the market (de Faria and Wraight 2007). The number has continued to increase, with almost 2700 arthropod pesticides introduced worldwide (Cock et al. 2010), in which about 230 species of biological control agents have been marketed and available for commercial use (van Lenteren 2012). The demand and commercial application of microbial pesticides have increased tremendously. Of 82 microbial biopesticides registered in Brazil, nearly 46% are mycoinsecticides (Mascarin et al. 2018). Fungal biopesticides contributed to a large portion of this increased demand and popularity in pest management in the past two decades (Jaronski and Mascarin 2017). Several products have already disappeared from the international marketplace because they were not commerically successful, but a substantial number of fungal species have been exploited (Kabaluk et al. 2010; Lacey et al. 2015) (Fig. 12).

De Faria and Wraight (2007) and Mascarin et al. (2018) listed representatives of mycoinsecticides derived from Beauveria, Isaria, Lecanicillium, and Metarhizium species found in the market. Most developed mycoinsecticdes were made for European and American markets, whereas only a few were aimed at the African and Asian markets (Table 5).

Table 5 Representative mycoinsecticides in the market (de Faria and Wraight 2007; Mascarin et al. 2018)

There have been continual obstacles and challenges to the development and commercialization of fungal biological control agents for use in controlling insect populations, ranging from gaps in understanding the basic biological knowledge to their potential socio-economic impact. Problems regarding the effectiveness of insecticides are linked to economic production. The increase in pest-resistance to chemical formulas has led to drastic environmental problems. New chemical insecticides are not being developed quickly enough, and therefore there is room for microbial insecticides, which are growing at the rapid pace of 10–25% per year (Starnes et al. 1993), within the market. Enhancing the virulence of potential fungal species is essential for mycoinsecticides to develop and reach their market potential.

The future of mycoinsecticides is promising, with continued research to increase pathogenic virulence of entomopathogenic fungi in order to achieve commercial success with genetic and physiological engineering. Further studies should be conducted to determine the fungal traits responsible for the effectiveness of mycoinsecticides, enhancement of their virulence, and development of eco-friendly and effective pest management strategies.

13. Biocontrol of nematodes and fungal nematicides

Plant-parasitic nematodes are parasites which cause severe damage to many economically important crops such as tomatoes, potatoes and wheat. For example, around US $80 billion of yield losses are caused annually by damage from plant root–knot nematodes, such as M. javanica and M. incognita (Li et al. 2007). Nematicidal chemicals that were once rather effective, such as methyl bromide, have ultimately been banned because they are broad-spectrum biocides that kill all life in the soil and contribute to the depletion of the ozone layer, thereby causing grave problems to the environment. Therefore, in recent years there have been great efforts in both academia and industry to find ecologically viable alternatives.

Nematophagous fungi are capable of controlling plant parasitic nematodes through antagonistic behaviour (Zaki and Siddiqui 1996). There are more than 700 species of nematophagous fungi, which are found in fungal taxa including Mucoromycota, Basidiomycota, Ascomycota and Chytridiomycota (Li et al. 2005; Degenkolb and Vilcinskas 2016). These nematophagous fungi are categorized into four groups according to their mode of parasitism: nematode-trapping (otherwise known as predacious); nematode egg and female parasites; endoparasitic; and toxin-producing fungi (Li et al. 2005; Degenkolb and Vilcinskas 2016). Nematode–trapping fungi form specific trapping structures on hypha, such as adhesive knobs, constricting rings and adhesive networks; these three trapping devices can be categorized further into seven types: simple adhesive branches, unstalked adhesive knobs, stalked adhesive knobs, non-constricting rings, constricting rings, two dimensional networks and three-dimensional networks (Rubner 1996).

The constricting ring trap is the most sophisticated morphological adaptation, which can be found in fungi that are no accommodated in the genus Drechslerella (Baral et al. 2018). When a nematode enters the ring, the three cells swell, forming three sphaerical structures that trap and immobilize the nematode (Jansson and Lopez-Llorca 2004). Endoparasitic fungi attack nematodes orally or by penetration of spores or zoospores through the cuticles of the nematode host (Moosavi et al. 2011). After infection, the hyphae develop inside the nematode and digests its content. For example, the spores of Catenaria anguillulae are ingested by sedentary nematodes such as Heterodera spp. The spores germinate in the esophagus and the mycelia then digest the nematodes; 10–12 h after the infection, zoosporangia develop to release new zoospores (Mankau 1980). The motile zoospores are adapted by having positive tropisms toward nematodes (Kumar et al. 2017). Nematode egg parasitic fungi play a key role in infecting the eggs of nematodes on two levels. Some fungi directly infect the nematode eggs by penetrating the eggshell, while others indirectly affect the content of eggs, such as larvae or embryos (Jansson and Lopez-Llorca 2004). Recent studies found that Ijuhya vitellina forms hyphae from the infected egg shells of the cereal cyst nematode Heterodera filipjevi to develop into microsclerotia (Ashrafi et al. 2017a). Monocillium gamsii and M. bulbillosum are two nematode-associated fungi parasitic to eggs of H. filipjevi (Ashrafi et al. 2017b). The first record of dark septate endophytes with nematicidal effects was reported from the new genus Polyphilus, represented by two new species (Ashrafi et al. 2018). Actually Polyphilus spp. have been isolated from nematode eggs as well as from healthy plant material.

Several studies related to nematode parasitic fungi that are specific to economically important crops have been conducted (Table 7). Cochliobolus sativus (on wheat and barley), Dendriphiopsis spp. (on tomato plants) and Drechmeria coniospora are some controlling agents for root knot disease caused by nematodes on wide variety of crops, especially tomatoes (Jansson et al. 1985). A combination of Trichoderma species and nematode-trapping fungi was most effective in controlling plant-parasitic nematodes through egg parasitism (Szabo 2014). Moreover, there are some fungi which are capable of controlling nematode diseases in animals (Zhang et al. 2007). For example, animals infected by plant-parasitic nematodes are fed with fungal mycelium containing chlamydospores of nematode trapping fungi, e.g. Duddingtonia flagrans (Zhang et al. 2007). When fed to the animals. these spores produce traps in the faeces and surrounding grasses to capture newly hatched nematode juveniles (Zhang et al. 2007). Purpureocillium lilacinum is capable of controlling root–knot nematodes such as M. javanica and M. incognita on tomato, eggplant and other vegetable crops (Moosavi 2014). Some studies have reported the antagonistic behaviour of Arthrobotrys dactyloides against root knot nematodes on tomato plants, but other experiments with Metacordyceps chlamydosporia did not significantly reduce nematode population (Nordbring-Hertz et al. 2011). Cochliobolus sativus was also reported to be an effective biological control agent in controlling nematodes in Botswana (Mubyana-John and Wright 2011). Table 6 is a synopsis of nematode parasitic fungi, and the unique trapping mechanisms of nematode-trapping fungi. The combination of Purpureocillium lilacinum (previously referred to as “Paecilomyces lilacinus”) and Dactylella lysipaga was experimentally proved to be antagonistic to the root–knot nematode Meloidogyne javanica as well as the cereal cyst nematodes Heterodera avenae and Radopholus similis on tomato barley and banana plants (Zhang et al. 2014a, b). In another study, the combination of Purpureocillium lilacinum and Monacrosporium lysipagum was shown to be antagonistic to Meloidogyne javanica, the cereal cyst nematode (Zhang et al. 2014a, b).

Table 6 Taxonomy of nematode parasitic fungi, their trapping mechanisms and parasitic nematodes.

Few studies conducted thus far have proven the efficiacy of nematode parasitic fungi; however, individually these fungi do not possess all the desirable characters required to serve as high potential nematode control agents. Thus combinations of nematophagous fungi can be more effective, as these combinations are capable of being parasitic in all stages of the nematode life cycle. Therefore, it is necessary to develop new techniques to facilitate research on nematode parasitic fungi, especially for tracing high potential strains in the environment. More studies are needed to improve and introduce more efficient strategies to produce biological control agents without harming non-targeted nematode species.

Liquid fermentation and solid fermentation are two methods of mass producing nematophagous fungi. Solid culturing is preferable for fungi that cannot produce spores in liquids (Zhang et al. 2014a, b). However, liquid culturing is widely used for the mass production of the spores and mycelium of targeted fungi (Zhang et al. 2014a, b). In fact, the combination of these two methods enhances the effectiveness of the mass production of fungi, as the liquid method can be used for producing mycelia and the solid method for producing conidia. The formulation of the fungal production is important in its commercialization as a bio control agent. Formulations are powders, wettable powders, emulsions, oil solutions, granular formulations, blending agents and microcapsules (Liu and Li 2004). Microencapsulation is a new method of commercializing bio control fungi (Patel et al. 2011). The latter researchers developed a novel capsule system using Hirsutella rhossiliensis. Jin and Custis (2011) also introduced a modified method for microencapsulation of Trichoderma conidia using sugar, which was then developed as a sprayable formulation.

Toxin-producing fungi secrete nematicidal metabolites to attack and immobilise nematodes before the development of hyphae inside the nematode (Degenkolb and Vilcinskas 2016). For example, Purpureocillium lilacinum produces acetic acid to immobilize juvenile parasitic nematodes (Djian et al. 1991). According to previous studies, more than 270 toxin-producing fungi have been recorded, including 230 nematicidal toxic compounds (Zhang et al. 2011a; Li et al. 2007). Recent examples include the report on the new genus and species Pseudobambusicola thailandica, which can control nematodes using its secondary metabolites, such as monocerin and deoxyphomalone (Rupcic et al. 2018). Linoleic acid is one of the nematicidal compounds that can be isolated from many fungi, including Arthrobotrys species, in which the production of this compound increases with the number of traps (Anke et al. 1995). Pleurotus pulmonarius and Hericium coralloides are two basidiomycetes that exhibit strong nematicidal effect against Caenorhabditis elegans. p-Anisaldehyde (46) and other aromatic metabolites, as well as fatty acids, were identified as active principles (Stadler et al. 1994) (Fig. 14).

Fig. 14
figure 14

Chemical structures of fungal metabolites with nematicidal activity

Metabolites with moderate nematicidal activity have been recently reported from a Sanghuangporus sp. collected in Kenya. In addition to 3, 14′-bihispidinyl and hispidin and the new dcerivative phelligridin L (49), with moderate effects on Caenorhabditis elegans (Chepkirui et al. 2018). Ophiotine (45), a depsipeptide from a species of the Phaeosphariaceae isolated from nemtatode eggs, was reported to have a moderate nematicidal effect on Heterodera filipjevi (Helaly et al. 2018a). Chaetomium globosum produces flavipin, which inhibits egg hatching and juvenile mobility of the root-knot nematode (Meloidogyne incognita) and the hatching of soybean cysts (Heterodera glycines) (Nitao et al. 2002). Chaetoglobosin A and its derivate 19-O-acetylchaetoglobosin A are two other recently demonstrated chemical compounds isolated from Ijuhya vitellina, a parasitite of the eggs of Heterodera filipjevi (Ashrafi et al. 2017a, b). However, the most important fungal nematicides found to date are (a) PF-1022A, a precursor of the semisynthetic drug emodepside (48), which is used in veterinary medicine (Jeschke et al. 2005); and (b) the cyclopeptide omphalotin A (47) from cultures of the basidiomycete genus Omphalotus, which was also developed as a nematicide against Meloidogyne, but did not yet make it to the market because of unfavourable costs of goods (Sandargo et al. 2019a).

Table 7 Commercial biological nematicides based on nematophagous fungi.

Many studies have shown the parasitic efficiency of nematode parasitic fungi, but it is necessary to develop IPM strategies to optimize the ability nematophagous fungi to colonize plant roots. High virulence strains and formulations are important for the development of more efficient commercial products. The utilization of the secondary metabolites of fungi as nematicides is not satisfactory at the commercial level as there are few bionematicides available in the market. On the other hand, integrated nematode management strategies can be implemented to improve the effectiveness of nematicidal action and minimize the use of chemical nematicides to the soil. Future bio products should be targeted not only for one species of nematode, but to disease complexes in concert with other pathogens like fungi, bacteria and viruses.

14. Biocontrol of weeds and herbicides from fungi

Weeds are plants that grow in a location where their presence has become undesirable due to their adverse effects on the ecosystem or human activities (Norris 1992; Kent 1994; Gadermaier et al. 2014). This is mainly due to the fact that when a plant is introduced to a new environment without the influence of their natural enemies they can grow without any obstruction and harm the native population by taking the form of a weed (Kendrick 1992). Thus, weeds can cause problems not only to the crop yield and quality, but also to the nature by invading native environment and its species composition. In order to ensure the balance of ecosystems, global crop production and food security; weed management is an important factor to be considered (Bjawa 2014).

During the early 1990s weed management was dominated by mechanical methods (Sommer 1996). The importance of mechanical weed control has become limited as it causes soil erosion and nutrient losses (Zimdahl 1993). Thus, chemical herbicides became the viable alternative. However, due to continuous use of the same herbicide with the same mode of action, herbicide resistance increased and for the last 20 years no chemical has been manufactured with a different mode of action than the previous products (Duke 2012). Researchers also identified the herbicidal toxic impact on non-target soil organisms which play an important role in degrading and decomposing organic matter (Subhani et al. 2015; Zain et al. 2013). Therefore, the need for biological weed control as well as development of bio-herbicides has become important.

Biological control of weeds (see the diagram in Fig. 15 for an example) is an effective and efficient alternative control method (Senthilkumar 2007). Biological weed control is used against invading plant species that pose a threat to endangered ecosystems and is designed to reduce the competition for nutrients and space by weeds. The aim of biological control of weeds is to decrease, suppress or kill the weed population using host specific insect herbivores or plant pathogens such as fungi, bacteria and viruses (Bailey et al. 2010).

Fig. 15
figure 15

Mechanism of actions implemented by antagonistic fungal species for management of rust diseased plants

The initial concept for using fungal pathogens in weed control was observed by a farmer in 1890 in the USA with the thistle population controlled by a rust fungus (Wilson 1969). A similar situation was recorded by Morris (1991) who observed that the Australian gall-forming rust fungus Uromycladium tepperianum helps to reduce the infestation of Acacia saligna at over 50 localities in South Africa. Until 1970 biocontrol of weeds was not considered as a solution or alternative to the massive use of chemical herbicides (Pointing and Hyde 2001).

Biological control refers to the planned introduction of an exotic bio control agent for permanent establishment for long term control in an area where weeds are problematic to the natural habitat (Evans 1998; Eilenberg et al. 2001). Fair examples for using fungi in biocontrol of weed are the successful use of the European rust fungus Phragmidium violaceum to control European blackberry (Rubus sp.) in Chile, or the use of Puccinia chondrillina to control Chondrilla juncea (rush skeleton weed) in Australia, which is considered as the most remarkable successes ever achieved with biocontrol (Kendrick 1992). These rust fungi are obligate biotrophs and cannot mass produce spores (or even grow) in an artificial medium. Therefore, small amounts of natural inoculum were introduced to the area and the weed control was obtained by natural spore production and dispersal (Cullen et al. 1973; Cullen and Delfosse 1985; Kendrick 1992; Espiau et al. 1998).

Inocula of plant pathogens, applied to weeds in a similar manner to synthetic herbicides are called bioherbicides. When fungi are involved, they are referred to as mycoherbicides (Boyetchko et al. 1996). These pathogens usually occur naturally on weeds in localities where they need to be controlled, but not in sufficient amounts. Therefore, fungal inocula are mass produced and sprayed on to the weeds. These mycoherbicide products must undergo a government-regulated registration process similar to chemical herbicides before they are released for public use (Evans 1998).

Mycoherbicide studies began in the 1940s in several countries with the aim to spread indigenous pathogenic fungal species on target weeds as a control measure (Pointing and Hyde 2001). In 1949, an attempt to control prickly pear cactus using Fusarium oxysporum was unsuccessful (Julien and Griffiths 1998). Kendrick (1992) mentioned another few examples where mass produced fungal propagules are applied as a mycoherbicides. A Colletotrichum gloeosporioides spore suspension was used to control northern joint vetch (Aeschynomene virginica) in rice and soybean fields in the USA. This was the first practical use of a fungus as a mycoherbicide that was later commercialised as “Collego”. Another example was water hyacinth, considered to be the worst aquatic weed in the world, but could be controlled by Acremonium zonatum and Cercospora rodmanii. However, during the 1950s, spores of Alternaria cuscutacidae were mass produced and applied to a dodder (Cuscuta sp.) (Wilson 1969, Julien and Griffiths. 1998). In 1963 China developed a mycoherbicide for dodder, using Colletotrichum gloeosporioides cf. cuscutae (Colletotrichum cuscutae) (Auld 1997; Kendrick 1992).

In the 5th edition of “A world catalogue of agents and their target weeds” by Winston et al. (2014), seven fungal species are mentioned that were developed as mycoherbicides and some of these are available as commercial products. According to Walker and Connick (1983) and Auld (1993) dew and temperature are the most important factors for primary infection of pathogen in order to obtain a successful disease development on the target weed. Some researchers have insisted that it is important to consider the time for secondary infection; which lead to a successive distribution of disease in the field (Boyette et al. (1979). According to Hasan and Ayres (1990) and El Morsy (2004), Stagnospora species on Calystegia sepium required only 3 weeks for control and Alternaria alternata on water hyacinth took 2 months.

Finding a new active fungal isolate for mycoherbicide production is not an easy task. There are a few important factors that need to be considered before mass production (O’Connell and Zoschke 1996). Mass availability of product, scientific testing for laboratory and field conditions, registration and commercializing procedures are necessary (Evans 1998). Within the past three decades research for improving this technology has increased. Even though the target weeds and phyto-pathogenic species identifications are still ongoing, interesting discoveries have surfaced overtime. According to Gan et al. (2013), the number of candidate genes found from the genomes of Colletotrichum gloeosporioides and Colletotrichum orbiculare, which were predicted to be involved in pathogenesis, showed the potential to be explotied as mycoherbcides. The discovery of genes in these two organisms related to the production of Indole acetic acid (IAA), a component of some of the well established herbicides, (see also chapter 21) showed that these can be converted to mycoherbicides (Gan et al. 2013). Some Phoma species were also considered as a successful candidate for the biocontrol of weeds. The ability of Phoma macrostoma to inhibit the growth of dicot plants was studied (Bailey et al. 2011, 2013; Smith et al. 2015). This fungus was used to control broadleaf weeds in turf systems in Canada and the USA. A registered commercial product of Phoma macrostoma is also available in Canada and USA (Evans et al. 2013).

The secondary metabolites produced by some fungi have been shown to have herbicidal activity. Castro de Souza et al. (2016) found several Diaporthe spp. from the Brazilian Pampa biome that have the ability to produce secondary metabolites with herbicidal activity. The genus Diaporthe is very rich in secondary metabolites, as recently summarised by Chepkirui and Stadler (2017).

Biological control may take several years to take effect and the effectiveness is influenced by a number of factors, such as climatic conditions, geographical region and management practices (Pointing and Hyde 2001). Among these, high initial cost, limited number of natural enemies and uncontrollable dissemination of biological control agents after its release in nature are considered as disadvantages (El-Sayed 2005). Biological control is particularly useful in areas where other conventional control methods are inappropriate, uneconomic or unachievable (Reznik 1996).

Different fungal species act as a promising source for the production of various compounds that can be used as potential herbicides. Since many of these toxins play a key role in the development of plant diseases (Poin